Transaction #29139 · Form 4 · 0001159036-26-000136
HALOZYME THERAPEUTICS, INC. · Stock award · Option to Purchase Common Stock
HALOZYME THERAPEUTICS, INC. · Transacted October 1, 2026 · Filed October 2, 2026
What does this filing report?
An SEC Form 4 filing for HALOZYME THERAPEUTICS, INC. records a stock award involving Option to Purchase Common Stock on October 1, 2026. The reported quantity was 1,775. The filing date is October 2, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- HALOZYME THERAPEUTICS, INC.
- Company CIK
- 0001159036
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 1,775
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 1,775
- Ownership description
- Not reported
- SEC acceptance time
- Oct 2, 2026, 4:43 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Daly James M ↗
Director
CIK 0001560782
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 1,775
- Conversion / exercise price
- 106.94
- Exercise date
- Not reported
- Expiration date
- October 1, 2036
Filing footnotes & remarks
- F1
- Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders.
- F2
- Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.